CHS – Bayer – ADVANCE Canada Research Program
The CHS – Bayer – ADVANCE Canada Research Program funds research to improve understanding and care for ageing Canadians with hemophilia, focusing on age-related health challenges.
Funder: Canadian Hemophilia Society
Due Dates: November 28, 2026 (Full application; annual deadline: November 28)
Funding Amounts: Up to $22,500 per project; maximum $45,000 for one year (typically one or two awards annually)
Summary: Supports research to address age-related health issues and improve care for the ageing hemophilia population in Canada.
Key Information: Applicants must be Canadian citizens or permanent residents affiliated with a Canadian university or not-for-profit health organization.
Description
The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program is designed to encourage research that addresses critical health issues faced by the ageing hemophilia population in Canada. The program aims to foster patient-centered, multidisciplinary research that advances understanding of age-related co-morbidities—such as cardiovascular disease, cancer, liver and bone disease, and chronic pain—among older Canadians living with hemophilia. By supporting studies that generate new insights and practical guidance, the program seeks to improve care strategies, inform policy, and enhance the quality of life for this demographic. Funded research should provide evidence-based information to healthcare practitioners, policymakers, and the public.
